A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of California, San Diego
Fate Therapeutics
Fate Therapeutics
Corregene Biotechnology Co., Ltd
National Cancer Institute (NCI)
Herlev Hospital